Novartis is to buy US biotech IFM Tre in a deal worth up to $1.575 billion, adding a potential drug for the fatty liver disease known as NASH to its pipeline. IFM Tre is a subsidiary of cancer biotech ...
London | British pension giant Nest will take a major stake in IFM Investors, the first time the $230 billion asset manager has expanded its shareholder register outside of Australia’s industry ...
Australian investment manager IFM Investors will wind down its domestic private equity unit in coming years, citing a lack of scale to make it commercially viable and a focus on other global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results